Royalty PharmaRPRX
About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees: 89
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
222% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $4.19M
9% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 127
0% more funds holding
Funds holding: 374 [Q1] → 374 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 60
8.91% less ownership
Funds ownership: 78.83% [Q1] → 69.92% (-8.91%) [Q2]
22% less capital invested
Capital invested by funds: $10.7B [Q1] → $8.33B (-$2.35B) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Goldman Sachs Chris Shibutani 63% 1-year accuracy 5 / 8 met price target | 82%upside $51 | Buy Maintained | 14 Aug 2024 |
Financial journalist opinion
Based on 7 articles about RPRX published over the past 30 days